MedTrace Logo

CLABSI Prevention With Tissue Adhesive

NCT05721677 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2024-10-02

No results posted yet for this study

Summary

Our aim is to test the effect of tissue adhesive application at the Central-line exit-site on CLABSI rates in high-risk pediatric congenital heart disease patients.

Conditions

  • Central-line Associated Blood Stream Infections (CLABSI)

Interventions

DEVICE

2-octyl cyanoacrylate based topical skin adhesive

Tissue adhesive on CVL exit-site

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Ovadia Dagan, Prof. M.D · Director PCICU, Schneider Children's Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
0 Days
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2026-03-15
Completion
2026-09-15
FDA Device
Yes

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05721677 on ClinicalTrials.gov